Photo taken from Yvonne Diaz/X
Jun 16, 2024, 17:20
Yvonne Diaz: EU Medicines Agency has approved Alecensa (alectinib) for early stage stage ALK+ lung cancer
Yvonne Diaz, Co-founder of Oncogene Cancer Research, shared a post on X:
“Great to see that EU Medicines Agency has approved Alecensa (alectinib) for early stage stage ALK+ lung cancer following the success of the ALINA clinical trial.
This highlights the need for biomarker testing across all stage non-small cell lung cancer patients.”
Additional information.
Source: Yvonne Diaz/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 17:57
Nov 14, 2024, 17:46
Nov 14, 2024, 17:46
Nov 14, 2024, 17:42
Nov 14, 2024, 17:14